A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Trial Profile

A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 May 2018 Planned End Date changed from 31 Mar 2019 to 30 Apr 2020.
    • 17 May 2018 Planned primary completion date changed from 31 Mar 2019 to 30 Apr 2020.
    • 17 May 2018 Planned initiation date changed from 30 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top